Heart failure (HF) is a progressive condition with an increasing prevalence, and the scientific
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …

The combination of neprilysin inhibitor sacubitril with the angiotensin II receptor 1 blocker
valsartan is the first agent from the angiotensin receptor neprilysin inhibitors (ARNI) class …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

Despite significant advances in the last 30 years in reducing morbidity and mortality from
heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based …

Background Sacubitril/valsartan, the first agent to be approved in a new class of drugs called
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …

Sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is the
first medication to demonstrate a mortality benefit in patients with chronic heart failure and …

Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …

Abstract Aims Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for
symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This …

Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …

Background: In the Prospective Comparison of angiotensin receptor neprilysin inhibitor
(ARNI) With ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure …